摘要
肝衰竭的临床内科救治缺乏特效用药,近期报道称粒细胞集落刺激因子(granulocyte colony-stimulating factor,G-CSF)能有效治疗酒精性肝炎和乙型肝炎(乙肝)肝衰竭,提高患者生存率。相关治疗机制研究显示G-CSF能动员骨髓造血干细胞(hematopoietic stem cells,HSCs)。其中,HSCs一方面直接分化为肝细胞;另一方面HSCs可能通过旁分泌方式改变肝脏微环境,强化内源性肝卵圆细胞反应性增生,启动内源性修复程序参与肝组织修复。G-CSF还可能通过抑制肝细胞凋亡/坏死及免疫调节,起到保护肝脏的作用。有必要开展多中心随机对照研究观察G-CSF治疗肝衰竭疗效及安全性的临床试验,为G-CSF推广应用提供高级别的循证医学依据。
The clinical medical treatment of liver failure is lack of effects of drugs. Recent reports of granulocyte colony-stimulating factor（G-CSF） can be effective in the treatment of liver failure induced by alcoholic hepatitis and hepatitis B virus（HBV）, and improve the survival rate of patients. The study of related therapeutic mechanism showed that G-CSF could mobilize bone marrow hematopoietic stem cells（HSCs）. Among them, on one hand, HSCs is directly differentiated into hepatocytes; on the other hand, HSCs may change the microenvironment of the liver by paracrine secretion, enhance endogenous hepatic oval cells proliferation and initiate endogenous repair procedures involved in liver tissue repair. G-CSF may also play a role in protecting the liver by inhibiting apoptosis / necrosis and regulating immune. At the same time, it is necessary to carry out a multicenter randomized controlled clinical trial of the therapeutic effects and safety of G-CSF for the treatment of liver failure, and to provide a high level basis of evidence-based medicine for the application of G-CSF.
出处
《传染病信息》
2016年第6期375-377,共3页
Infectious Disease Information
基金
首都特色临床应用研究课题(Z131107002213157)
作者简介
[通讯作者]胡瑾华，E-mail：hjh@medmail．com.cn
